Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
- Conditions
- Multiple SclerosisPrimary Progressive Multiple Sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)Non-Active Secondary Progressive Multiple SclerosisNon-Active SPMSAutoimmune Diseases of the Nervous SystemNervous System DiseasesAutoimmune DiseasesDemyelinating DiseasesImmune System Diseases
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Indapta Therapeutics, INC.
- Target Recruit Count
- 34
- Registration Number
- NCT06677710
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States
🇺🇸Stanford University, Stanford, California, United States
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06640582
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 141
- Registration Number
- NCT06598371
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06538012
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 75
- Registration Number
- NCT06532799
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06532812
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06530303
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Target Recruit Count
- 30
- Registration Number
- NCT06504901
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Target Recruit Count
- 23
- Registration Number
- NCT06504875
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
- Target Recruit Count
- 23
- Registration Number
- NCT06302062
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Gaungdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.